These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29701272)

  • 1. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer.
    Hu Q; Qin Y; Xiang J; Liu W; Xu W; Sun Q; Ji S; Liu J; Zhang Z; Ni Q; Xu J; Yu X; Zhang B
    Cell Prolif; 2018 Aug; 51(4):e12456. PubMed ID: 29701272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer.
    Dash S; Ueda T; Komuro A; Honda M; Sugisawa R; Okada H
    Cell Death Dis; 2024 Feb; 15(2):131. PubMed ID: 38346958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
    Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
    Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
    Sebastiani V; Ricci F; Rubio-Viqueira B; Kulesza P; Yeo CJ; Hidalgo M; Klein A; Laheru D; Iacobuzio-Donahue CA
    Clin Cancer Res; 2006 Apr; 12(8):2492-7. PubMed ID: 16638857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.
    DeNicola GM; Karreth FA; Humpton TJ; Gopinathan A; Wei C; Frese K; Mangal D; Yu KH; Yeo CJ; Calhoun ES; Scrimieri F; Winter JM; Hruban RH; Iacobuzio-Donahue C; Kern SE; Blair IA; Tuveson DA
    Nature; 2011 Jul; 475(7354):106-9. PubMed ID: 21734707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK.
    Patel GK; Khan MA; Bhardwaj A; Srivastava SK; Zubair H; Patton MC; Singh S; Khushman M; Singh AP
    Br J Cancer; 2017 Feb; 116(5):609-619. PubMed ID: 28152544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kinase.
    Kuroda H; Tachikawa M; Uchida Y; Inoue K; Ohtsuka H; Ohtsuki S; Unno M; Terasaki T
    Eur J Pharm Sci; 2017 May; 103():116-121. PubMed ID: 28215943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
    Saiki Y; Yoshino Y; Fujimura H; Manabe T; Kudo Y; Shimada M; Mano N; Nakano T; Lee Y; Shimizu S; Oba S; Fujiwara S; Shimizu H; Chen N; Nezhad ZK; Jin G; Fukushige S; Sunamura M; Ishida M; Motoi F; Egawa S; Unno M; Horii A
    Biochem Biophys Res Commun; 2012 Apr; 421(1):98-104. PubMed ID: 22490663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation.
    Ju HQ; Gocho T; Aguilar M; Wu M; Zhuang ZN; Fu J; Yanaga K; Huang P; Chiao PJ
    Mol Cancer Ther; 2015 Mar; 14(3):788-98. PubMed ID: 25527634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1.
    Tian L; Lu Y; Yang T; Deng Z; Xu L; Yao W; Ma C; Li X; Zhang J; Liu Y; Wang J
    Redox Biol; 2019 Apr; 22():101149. PubMed ID: 30822690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer.
    Tuerhong A; Xu J; Wang W; Shi S; Meng Q; Hua J; Liu J; Zhang B; Yu X; Liang C
    Surgery; 2024 May; 175(5):1264-1275. PubMed ID: 38302326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
    Maity G; Ghosh A; Gupta V; Haque I; Sarkar S; Das A; Dhar K; Bhavanasi S; Gunewardena SS; Von Hoff DD; Mallik S; Kambhampati S; Banerjee SK; Banerjee S
    Mol Cancer Ther; 2019 Apr; 18(4):788-800. PubMed ID: 30787177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth.
    Vernejoul F; Ghénassia L; Souque A; Lulka H; Drocourt D; Cordelier P; Pradayrol L; Pyronnet S; Buscail L; Tiraby G
    Mol Ther; 2006 Dec; 14(6):758-67. PubMed ID: 17000136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
    Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
    Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
    Costantino CL; Witkiewicz AK; Kuwano Y; Cozzitorto JA; Kennedy EP; Dasgupta A; Keen JC; Yeo CJ; Gorospe M; Brody JR
    Cancer Res; 2009 Jun; 69(11):4567-72. PubMed ID: 19487279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
    McAllister F; Pineda DM; Jimbo M; Lal S; Burkhart RA; Moughan J; Winter KA; Abdelmohsen K; Gorospe M; Acosta Ade J; Lankapalli RH; Winter JM; Yeo CJ; Witkiewicz AK; Iacobuzio-Donahue CA; Laheru D; Brody JR
    Cancer Biol Ther; 2014 Jun; 15(6):688-98. PubMed ID: 24618665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment.
    Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Ohtsuka H; Kamiie J; Abe T; Unno M; Terasaki T
    Mol Pharm; 2015 Sep; 12(9):3282-91. PubMed ID: 26280109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines.
    Si S; Liao Q; Zhao YP; Hu Y; Zhang Q; You LL
    Chin Med J (Engl); 2011 Feb; 124(3):419-22. PubMed ID: 21362344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling.
    Zhou Y; Wang K; Zhou Y; Li T; Yang M; Wang R; Chen Y; Cao M; Hu R
    Redox Biol; 2020 Jan; 29():101390. PubMed ID: 31785531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells.
    Hodzic J; Giovannetti E; Diosdado B; Adema AD; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1214-22. PubMed ID: 22132977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.